Platinum Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-395,954
| Closed | -$2.09M | – | 127 |
|
|
2025
Q1 | $2.09M | Sell |
395,954
-337,057
| -46% | -$1.78M | 0.12% | 51 |
|
|
2024
Q4 | $4.96M | Buy |
733,011
+546,929
| +294% | +$3.7M | 0.29% | 37 |
|
|
2024
Q3 | $1.23M | Sell |
186,082
-209,591
| -53% | -$1.38M | 0.06% | 75 |
|
|
2024
Q2 | $2.97M | Sell |
395,673
-1,404,796
| -78% | -$10.5M | 0.12% | 55 |
|
|
2024
Q1 | $18M | Sell |
1,800,469
-473,495
| -21% | -$4.72M | 0.72% | 23 |
|
|
2023
Q4 | $22.4M | Sell |
2,273,964
-61,168
| -3% | -$603K | 0.91% | 24 |
|
|
2023
Q3 | $17.9M | Sell |
2,335,132
-376,016
| -14% | -$2.88M | 0.7% | 28 |
|
|
2023
Q2 | $20.3M | Sell |
2,711,148
-59,303
| -2% | -$443K | 0.7% | 31 |
|
|
2023
Q1 | $18.5M | Buy |
2,770,451
+60,112
| +2% | +$401K | 0.64% | 31 |
|
|
2022
Q4 | $20.9M | Buy |
2,710,339
+458,368
| +20% | +$3.53M | 0.8% | 27 |
|
|
2022
Q3 | $24M | Sell |
2,251,971
-283,651
| -11% | -$3.02M | 1% | 25 |
|
|
2022
Q2 | $20.6M | Buy |
2,535,622
+399,018
| +19% | +$3.25M | 0.78% | 27 |
|
|
2022
Q1 | $15.3M | Buy |
2,136,604
+692,741
| +48% | +$4.96M | 0.47% | 37 |
|
|
2021
Q4 | $24.7M | Buy |
1,443,863
+782,160
| +118% | +$13.4M | 0.69% | 27 |
|
|
2021
Q3 | $15.2M | Buy |
661,703
+189,151
| +40% | +$4.35M | 0.43% | 36 |
|
|
2021
Q2 | $17.2M | Buy |
+472,552
| New | +$17.2M | 0.4% | 40 |
|